Theseus Pharmaceuticals, Inc. announced the appointment of Steven Stein, M.D. to its Board of Directors. Dr. Stein currently serves as Executive Vice President, Chief Medical Officer of the global biopharmaceutical company, Incyte, where he develops strategy for Incyte's therapeutic candidates and oversees verticals including clinical development, regulatory affairs and medical affairs. Previously, he worked at Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology.

Dr. Stein previously worked at GSK (formerly GlaxoSmithKline) as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an assistant professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in hematology and oncology. Dr. Stein has served as a member of Kura Oncology's Board of Directors since January 2017.

He earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.